Autolus Therapeutics plc ADR Dossier - Source-backed chat

Autolus Therapeutics plc ADR

AUTLNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.68

Intrinsic Value $3.06median of 2 methodsbased on filings through 30 Jun 2026

Market Price $1.94Price as of 30 Sep 2026

Significantly undervaluedIntrinsic value is 58% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+58%)

Data confidence Sign in to view data confidence

Market Cap $516.4M

Enterprise Value $424.9M

Shares Outstanding 266.2M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Autolus Therapeutics plc (NASDAQ: AUTL) is transitioning from a clinical-stage R&D biotech to a commercial-stage leader in programmed T-cell immunotherapies. The successful launch of AUCATZYL (obe-cel) in the US and UK has driven a significant inflection in product revenues, leading to the company's first-ever positive gross margin in Q1 2026. While the company remains loss-making overall, a strategic 13% workforce reduction and operational efficiency plan initiated in April 2026 are designed to accelerate the path to profitability for its acute lymphoblastic leukemia (ALL) franchise by 2028. Backed by a cash runway extending into Q4 2027 and high-value pipeline readouts in autoimmune indications (such as progressive MS and lupus nephritis) expected between late 2026 and 2028, Autolus presents a compelling risk-reward profile for growth-oriented biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$8.73

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

AUCATZYL commercial adoption slows due to manufacturing bottlenecks, logistical challenges in patient cell turnaround, or intense competition from established CAR-T therapies. Restructuring charges exceed estimates, and operating expenses remain high, depleting the cash runway faster than projected and forcing a highly dilutive equity raise before late 2027. Clinical readouts for BOBCAT or ALARIC by year-end 2026 show safety concerns (e.g., high-grade CRS or ICANS) or insufficient efficacy, limiting the platform's expansion potential.

Base CaseCentral scenario

AUCATZYL commercial adoption continues to scale in the US and UK, meeting the reiterated full-year 2026 net product revenue guidance of $120 million to $135 million. The company successfully executes its 13% workforce reduction, realizing $15 million in annualized operating expense savings starting in 2027. Initial Phase 1 readouts for BOBCAT (progressive MS) and ALARIC (light-chain amyloidosis) by year-end 2026 demonstrate favorable safety and early efficacy, validating the expansion of obe-cel into autoimmune and broader indications.

Bull CaseUpside scenario

The bull case centers on the commercial launch of AUCATZYL (obe-cel) for adult B-ALL, its expansion into high-value autoimmune indications like lupus nephritis and progressive multiple sclerosis, and strategic partnerships (e.g., BioNTech, Blackstone) that validate its modular CAR-T platform and extend its cash runway.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum with AUCATZYL net product revenue rising to $26.2 million in Q1 2026, supporting a shift to positive gross margin.
Reiterated full-year 2026 AUCATZYL revenue guidance of $120 million to $135 million, representing substantial year-over-year growth from $74 million in 2025.
Strategic cost-reduction initiative (13% workforce reduction) expected to save $15 million annually starting in 2027, accelerating the path to ALL franchise profitability by 2028.
Robust cash runway of $229.4 million as of March 31, 2026, sufficient to fund operations into Q4 2027.
High-value pipeline expansion into autoimmune diseases (lupus nephritis, progressive MS) with multiple clinical catalysts expected between late 2026 and 2028.

Key Investment Risks

The company remains deeply loss-making, reporting a net loss of $71.6 million in Q1 2026.
Commercial execution risks, including the complexity of manufacturing and delivering autologous CAR-T therapies with consistent turnaround times.
Potential clinical and regulatory setbacks in pipeline programs (e.g., BOBCAT, ALARIC, CATULUS, LUMINA).
Risk of future equity dilution if commercial revenues do not scale fast enough to achieve self-sustainability before the cash runway ends in Q4 2027.

Thesis Invalidation Triggers

Failure to meet the lower bound of the 2026 AUCATZYL net product revenue guidance ($120 million).
Severe safety signals (such as high-grade CRS or ICANS) emerging in the real-world ROCCA consortium data or ongoing clinical trials.
Inability to achieve positive gross margin expansion or realize the projected $15 million in annualized operating savings from the restructuring plan.
Significant delays in clinical readouts for the BOBCAT (progressive MS) or ALARIC (amyloidosis) trials beyond year-end 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.